QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
Log in
NASDAQ:NBIX

Neurocrine Biosciences Stock Forecast, Price & News

$96.16
-1.54 (-1.58 %)
(As of 09/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$95.42
Now: $96.16
$98.94
50-Day Range
$97.40
MA: $108.01
$116.67
52-Week Range
$72.14
Now: $96.16
$136.26
Volume822,318 shs
Average Volume826,472 shs
Market Capitalization$8.97 billion
P/E Ratio45.57
Dividend YieldN/A
Beta1.22
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Its product candidates in clinical development include elagolix that is in Phase III clinical trial for Uterine Fibroids; opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase II clinical trial for the treatment of congenital adrenal hyperplasia. The company's product candidates also comprise VMAT2 Inhibitors and which are in Phase I clinical trial for neurology/psychiatry disorders. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL - Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders; and a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of VY-AADC program for Parkinson's disease and VY-FXN01 program for Friedreich's ataxia. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Read More
Neurocrine Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.16 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NBIX
CUSIP64125C10
Phone858-617-7600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$788.10 million
Cash Flow$0.62 per share
Book Value$6.92 per share

Profitability

Net Income$37.01 million

Miscellaneous

Employees585
Market Cap$8.97 billion
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$96.16
-1.54 (-1.58 %)
(As of 09/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

How has Neurocrine Biosciences' stock been impacted by Coronavirus?

Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NBIX stock has increased by 11.9% and is now trading at $96.16.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Neurocrine Biosciences?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 8 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Neurocrine Biosciences
.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Neurocrine Biosciences
.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its quarterly earnings results on Monday, August, 3rd. The company reported $0.81 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.65 by $0.16. The company had revenue of $302.40 million for the quarter, compared to analyst estimates of $261.66 million. Neurocrine Biosciences had a return on equity of 39.22% and a net margin of 20.36%. The company's quarterly revenue was up 64.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.71 EPS.
View Neurocrine Biosciences' earnings history
.

What price target have analysts set for NBIX?

20 brokerages have issued 1 year price objectives for Neurocrine Biosciences' shares. Their forecasts range from $108.00 to $161.00. On average, they expect Neurocrine Biosciences' share price to reach $137.39 in the next twelve months. This suggests a possible upside of 42.9% from the stock's current price.
View analysts' price targets for Neurocrine Biosciences
.

Who are some of Neurocrine Biosciences' key competitors?

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Gilead Sciences (GILD), AbbVie (ABBV), Netflix (NFLX), Walt Disney (DIS), salesforce.com (CRM), Square (SQ) and Tesla (TSLA).

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the following people:
  • Dr. Kevin C. Gorman, CEO & Director (Age 61)
  • Mr. Matthew C. Abernethy, Chief Financial Officer (Age 39)
  • Dr. Haig P. Bozigian, Chief Devel. Officer (Age 61)
  • Mr. Eric S. Benevich, Chief Commercial Officer (Age 54)
  • Dr. Christopher F. O'Brien, Exclusive Consultant (Age 62)

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $96.16.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $8.97 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is www.neurocrine.com.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.